ChemoCentryx, Inc. (NASDAQ:CCXI) was the recipient of some unusual options trading activity on Tuesday. Stock investors purchased 5,543 call options on the stock. This represents an increase of 981% compared to the typical daily volume of 513 call options.

Several analysts have recently issued reports on CCXI shares. Raymond James boosted their price objective on shares of ChemoCentryx from $119.00 to $120.00 and gave the company a “strong-buy” rating in a research note on Monday, March 8th. HC Wainwright lifted their price objective on ChemoCentryx from $83.00 to $101.00 and gave the company a “buy” rating in a research note on Tuesday, March 2nd. TheStreet lowered shares of ChemoCentryx from a “c-” rating to a “d” rating in a report on Tuesday, March 2nd. Finally, Stifel Nicolaus began coverage on shares of ChemoCentryx in a research report on Monday, March 8th. They issued a “buy” rating and a $93.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. ChemoCentryx presently has a consensus rating of “Buy” and a consensus price target of $80.78.

Shares of CCXI traded down $23.51 during trading hours on Tuesday, hitting $25.31. The stock had a trading volume of 525,171 shares, compared to its average volume of 491,612. ChemoCentryx has a 52 week low of $44.28 and a 52 week high of $70.29. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -37.31 and a beta of 1.70. The company’s fifty day moving average is $49.99 and its two-hundred day moving average is $57.15. The company has a debt-to-equity ratio of 0.05, a current ratio of 10.12 and a quick ratio of 10.12.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Thursday, April 29th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.03). ChemoCentryx had a negative return on equity of 17.23% and a negative net margin of 58.10%. Equities analysts predict that ChemoCentryx will post -0.72 EPS for the current fiscal year.

In other ChemoCentryx news, Director Thomas A. Edwards sold 400 shares of the firm’s stock in a transaction that occurred on Tuesday, February 9th. The shares were sold at an average price of $70.04, for a total value of $28,016.00. Following the completion of the transaction, the director now owns 120,957 shares of the company’s stock, valued at approximately $8,471,828.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pui San Kwan sold 3,347 shares of the stock in a transaction on Thursday, February 4th. The shares were sold at an average price of $65.00, for a total value of $217,555.00. Following the completion of the sale, the insider now owns 4,621 shares in the company, valued at $300,365. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,626 shares of company stock worth $3,632,810. 9.30% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of the business. Valeo Financial Advisors LLC bought a new stake in shares of ChemoCentryx in the fourth quarter valued at approximately $37,000. Harbor Investment Advisory LLC lifted its position in ChemoCentryx by 28.2% during the first quarter. Harbor Investment Advisory LLC now owns 1,091 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 240 shares during the period. Penserra Capital Management LLC increased its holdings in ChemoCentryx by 169.5% in the 4th quarter. Penserra Capital Management LLC now owns 1,590 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,000 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of ChemoCentryx by 19.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,130 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 350 shares during the period. Finally, Pacer Advisors Inc. raised its position in ChemoCentryx by 39.9% during the fourth quarter. Pacer Advisors Inc. now owns 2,259 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 644 shares in the last quarter. Hedge funds and other institutional investors own 80.67% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

Featured Article: What sectors are represented in the Hang Seng index?

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with's FREE daily email newsletter.